All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Association of BMI on outcomes in adolescent and young adult patients with ALL
By Megan Kelly
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
While this association has been reported, there is limited data available on the impact of obesity on metabolic toxicities, disease response, and survival in adolescents and young adults (AYAs) with ALL treated with pediatric regimens. Here, we summarize a study by Shimony et al.1 investigating the association between body mass index (BMI) and toxicities and survival among AYAs with ALL treated with Dana-Farber Cancer Institute (DFCI) regimens.
Study design
Patients treated on four sequential multicenter DFCI ALL consortium protocols were included in this analysis (Figure 1).
Figure 1. ALL DFCI consortium treatment protocols*†‡
CNS, central nervous system; PEG, pegylated.
*Adapted from Shimony, et al.1
†Including pediatric protocols (00-001 and 05-001) and pediatric-inspired protocols (01-175 and 06-254).
‡Asparaginase administration is marked in purple.
The standard measure of obesity was patient BMI at diagnosis, calculated based on Center for Disease Control (CDC) guidelines (Table 1).
Table 1. Measure of obesity*
|
BMI categories |
Patients aged 2–20 years, BMI per age-adjusted percentiles |
Patients aged ≥20 years, BMI (kg/m2) |
|---|---|---|
|
Underweight† |
<5% percentile |
<18.5 kg/m2 |
|
Normal† |
5%–84.99% percentiles |
18.5–24.99 kg/m2 |
|
Overweight |
85%–94.99% percentiles |
25–29.99 kg/m2 |
|
Obese |
≥95% percentile |
≥30 kg/m2 |
|
BMI, body mass index |
||
Results
A total of 388 patients with a median age of 24 years (range, 15–50 years) were included. More than half of patients were in the underweight (n = 10) or normal BMI range (n = 197) at diagnosis (normal BMI group, n = 207), and the remaining patients had a BMI of overweight (n = 97) or obese (n = 84; combined overweight/obese group, n = 181).
Toxicities
The toxicity analysis was based on 353 patients. The rate of any Grade 3/4 hepatotoxicity and any Grade 3/4 hyperglycemia was higher in patients with an overweight/obese vs those with a normal BMI. There was no significant difference in Grade 3/4 hypertriglyceridemia between BMI groups, as shown in Figure 2.
Figure 2. Grade 3/4 toxicity rates between BMI groups*
TG, hypertriglyceridemia.
*Adapted from Shimony, et al.1
Response, survival, and relapse
Complete response
A total of 87% of patients achieved complete response with no difference between BMI groups (p = 0.84).
Overall survival
The 4-year overall survival (OS) was 74% and was higher in younger vs older AYA patients (79%; 95% confidence interval [CI], 73–84 vs 64%; 95% CI, 55–72; p = 0.003), and in patients with normal vs overweight/obese BMI (83%; 95% CI, 77–88 vs 64%; 95% CI, 56–71; p = 0.0001).
Separate analyses were conducted due to an association between the age group and BMI group. In the patients with normal BMI, there was a similar OS between younger vs older AYAs. In contrast, OS was higher in younger vs older AYAs who were overweight/obese (Figure 3).
Figure 3. 4-year OS*
BMI, body mass index; CI, confidence interval.
*Data from Shimony, et al.1
Event-free survival
The 4-year event-free survival (EFS) was 70% and was higher in patients with a normal BMI vs those with an overweight/obese BMI (77%; 95% CI, 70–83 vs 63%; 95% CI, 55–70; p = 0.003).
The 4-year EFS rates were similar for younger and older AYAs with normal BMI. In contrast, the EFS rate was numerically higher in younger vs older AYAs who were overweight/obese; however, this was not statistically significant (Figure 4).
Figure 4. 4-year EFS*
BMI, body mass index; CI, confidence interval.
*Data from Shimony, et al.1
Relapse
The 4-year cumulative incidence of relapse (CIR) was 20.7% (95% CI, 15.9–25.9) and was not statistically different between BMI groups. Although 4-year CIR was similar in younger and older patients in the normal BMI group (17.9%; 95% CI, 10.6–26.9 vs 18.8%; 95% CI, 8.0–33.2; p = 0.89), the 4-year CIR was numerically lower in younger vs older patients in the overweight/obese group (17.1%; 95% CI, 9.0–27.5 vs 30.1%; 95% CI, 19.6–41.2; p = 0.13).
The 4-year cumulative incidence of non-relapse mortality was 7.3% (95% CI, 4.6–10.8) and was lower in patients with normal BMI vs those with overweight/obese BMI (2.8%; 95% CI, 0.9–6.7; vs 11.7%; 95% CI, 6.9–17.8; p = 0.006). The cumulative incidence of non-relapse mortality was similar between younger and older patients in each BMI group.
Multivariable analysis
- In the multivariable analysis, the following variables were significantly associated with worse OS:
- BMI (overweight/obese vs normal; hazard ratio [HR], 2.38; 95% CI, 1.56–3.63; p < 0.0001)
- White blood cell count (≥30,000 × 109/L vs <30,000 × 109/L; HR, 1.79; 95% CI, 1.20–2.69; p = 0.005)
- Immunophenotype (B vs T; HR, 2.27; 95% CI, 1.26–4.09; p = 0.006)
- Hypertriglyceridemia was significantly associated with improved OS (HR, 0.33; 95% CI, 0.18–0.61; p < 0.0001).
- Allogeneic hematopoietic stem cell transplantation was significantly associated with worse OS in the univariate analysis (HR, 2.04; 95 CI, 1.26–3.30; p = 0.004) but not in the multivariable analysis (HR, 1.31; 95% CI, 0.80–2.14; p = 0.28).
- Age was significantly associated with worse OS in the univariate analysis (HR, 1.03; 95% CI, 1.01–1.05; p = 0.003) but not in the multivariable analysis.
- There was a trend toward worse OS with Grade 3/4 hyperglycemia (HR, 1.51; 95% CI, 0.99–2.28; p = 0.054).
Conclusion
In this study of AYA patients treated on a pediatric regimen, being overweight or obese was associated with higher non-relapse mortality, worse EFS, and worse OS. In particular, a higher BMI was associated with high relapse rates and poor survival among the older AYAs (aged >30 years). The study also demonstrated that hypertriglyceridemia was associated with improved survival and decreased risk of relapse. These results warrant further research on the impact of BMI on treatment toxicities and outcomes among patients of all ages with ALL.
- Shimony S, Flamand Y, Valtis YK, et al. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023;7(18):5234-5245. DOI: 10.1182/bloodadvances.2023009976
More about...
Your opinion matters
6 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox